Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 64

Lung Disease

Categories: Blood diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 11 14 16
Lung Diseases 53 41 43 14 71
Disorder of Lung 28 5
Abnormality of the Lung 5

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:850
MeSH 43 D008171
NCIt 49 C3198
SNOMED-CT 68 266374002
ICD10 31 J60-J70 J98.4
UMLS 71 C0024115
Sources

Summaries for Lung Disease

About this section

MedlinePlus: 41 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary: Lung Disease, also known as lung diseases, is related to interstitial lung disease and interstitial lung disease 2, and has symptoms including hemoptysis, dyspnea and apnea. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Innate Immune System. The drugs Cathine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include lung, bone marrow and heart, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.
Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1705)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 33.9 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
2 interstitial lung disease 2 33.7 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
3 pulmonary disease, chronic obstructive 33.5 TNF SFTPD SFTPB SERPINA1 PRTN3 IL1B
4 extrinsic allergic alveolitis 33.2 TNF SFTPD MUC5B ELANE CXCL8 CCL2
5 interstitial pneumonitis, desquamative, familial 33.2 SFTPD SFTPC SFTPB SFTPA2 MUC5B ABCA3
6 pulmonary fibrosis 33.2 SFTPD SFTPC SFTPA2 SFTPA1 MUC5B IL1B
7 anthracosis 33.1 TNF MUC5B IL1B CXCL8 CCL2
8 pneumoconiosis 33.1 TNF SERPINA1 IL1B IL10 CXCL8 CCL2
9 rheumatoid arthritis interstitial lung disease 33.0 TNF SFTPD MUC5B
10 cystic fibrosis 33.0 TNF SFTPD SFTPC SFTPB SFTPA1 SERPINA1
11 alpha-1-antitrypsin deficiency 33.0 TNF SERPINA1 PRTN3 ELANE CXCL8 CFTR
12 respiratory failure 32.9 TNF SFTPD SFTPC SFTPB SERPINA1 IL1B
13 pneumonia 32.9 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
14 pulmonary hypertension 32.9 TNF SFTPC SFTPB SERPINA1 ELANE CCL2
15 asthma 32.8 TNF SFTPD SFTPC SFTPB SERPINA1 PRTN3
16 nonspecific interstitial pneumonia 32.7 SFTPD SFTPC SFTPA2 PRTN3 MUC5B IFIH1
17 aspergillosis 32.7 TNF SFTPD SFTPA2 SFTPA1 IL1B IL10
18 bronchopulmonary dysplasia 32.7 SFTPB ELANE CXCL8
19 bronchiolitis 32.7 TNF SFTPD IL1B IL10 CXCL8 CCL2
20 bird fancier's lung 32.7 SFTPD MUC5B
21 systemic scleroderma 32.6 TNF PRTN3 IL1B IL10 IFIH1 CXCL8
22 cryptogenic organizing pneumonia 32.6 SFTPD SFTPC PRTN3 IFIH1 CXCL8
23 surfactant dysfunction 32.6 SFTPC SFTPB ABCA3
24 pulmonary alveolar microlithiasis 32.6 SFTPD SFTPB ABCA3
25 pulmonary hemosiderosis 32.5 SFTPC SFTPB PRTN3 ABCA3
26 bronchiolitis obliterans 32.5 TNF SFTPD IL10 CXCL8
27 pulmonary alveolar proteinosis 32.5 TNF SFTPD SFTPC SFTPB SFTPA1 IL10
28 silicosis 32.5 TNF SFTPD IL1B IL10 CXCL8 CCL2
29 acute interstitial pneumonia 32.4 SFTPD SFTPC SFTPA2 MUC5B IFIH1
30 common variable immunodeficiency 32.4 TNF SERPINA1 IL1B IL10
31 respiratory distress syndrome in premature infants 32.4 SFTPC SFTPB SFTPA1 ABCA3
32 bronchiectasis 32.4 TNF SERPINA1 IL1B ELANE CXCL8 CFTR
33 connective tissue disease 32.4 TNF SFTPD PRTN3 IL1B IL10 CXCL8
34 pulmonary immaturity 32.4 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
35 pulmonary interstitial emphysema 32.4 SFTPD SFTPC SFTPB ABCA3
36 hereditary pulmonary alveolar proteinosis 32.3 SFTPC SFTPB ABCA3
37 sleep disorder 32.3 TNF IL1B IL10 CXCL8
38 adult respiratory distress syndrome 32.3 TNF SFTPD SFTPC SFTPB IL1B IL10
39 meconium aspiration syndrome 32.3 TNF SFTPB CXCL8 ABCA3
40 hermansky-pudlak syndrome 32.3 SFTPC SFTPB SFTPA2 ABCA3
41 sarcoidosis 1 32.3 TNF SFTPD PRTN3 IL1B IL10 CCL2
42 rheumatoid arthritis 32.2 TNF PRTN3 IL1B IL10 ELANE CXCL8
43 bronchitis 32.2 TNF SERPINA1 IL1B IL10 ELANE CXCL8
44 arthritis 32.2 TNF IL1B IL10 CXCL8 CCL2
45 autoimmune disease 32.0 TNF PRTN3 IL1B IL10 CCL2
46 idiopathic interstitial pneumonia 31.9 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
47 allergic disease 31.8 TNF SFTPD IL1B IL10 CXCL8
48 vasculitis 31.8 TNF SERPINA1 PRTN3 IL1B IL10 ELANE
49 gastroesophageal reflux 31.8 TNF IL1B ELANE CXCL8 CCL2
50 pulmonary tuberculosis 31.7 TNF IL1B IL10 CCL2

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


hemoptysis; dyspnea; apnea; snoring; coughing; labored breathing

MGI Mouse Phenotypes related to Lung Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 ABCA3 CCL2 CFTR ELANE IFIH1 IL10
2 immune system MP:0005387 10.17 CCL2 CFTR ELANE IFIH1 IL10 IL1B
3 respiratory system MP:0005388 10.03 ABCA3 CFTR DYNC2H1 IL10 ITGA3 MUC5B
4 hematopoietic system MP:0005397 9.97 CCL2 CFTR DYNC2H1 ELANE IFIH1 IL10
5 neoplasm MP:0002006 9.95 CCL2 ELANE IL10 IL1B ITGA3 SFTPC
6 mortality/aging MP:0010768 9.89 ABCA3 CCL2 CFTR DYNC2H1 ELANE IFIH1
7 integument MP:0010771 9.28 CCL2 CFTR ELANE IFIH1 IL10 IL1B
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 642)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718
4
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
5
Tazobactam Approved Phase 4 89786-04-9 123630
6
Piperacillin Approved Phase 4 66258-76-2 43672
7
Beractant Approved Phase 4 108778-82-1
8
Cefuroxime Approved Phase 4 55268-75-2 5479529
9
Benzylpenicillin Approved, Vet_approved Phase 4 61-33-6 5904
10
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
18
Sultamicillin Approved, Investigational Phase 4 76497-13-7 2175
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
21
Glycopyrronium Approved, Investigational, Vet_approved Phase 4 596-51-0, 740028-90-4 3494
22
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
23
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
26
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
27
Lactitol Approved, Investigational Phase 4 585-86-4 157355
28
Phenylephrine Approved Phase 4 59-42-7 6041
29
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
30
Norflurane Approved, Experimental Phase 4 811-97-2 13129
31
Theophylline Approved Phase 4 58-55-9 2153
32
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
33
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
34
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
35
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
36
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
37
Remifentanil Approved Phase 4 132875-61-7 60815
38
Desflurane Approved Phase 4 57041-67-5 42113
39
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
40
Fosinopril Approved Phase 4 98048-97-6 55891 9601226
41
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
42
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
43
Celiprolol Approved, Investigational Phase 4 56980-93-9 2663
44
Ledipasvir Approved Phase 4 1256388-51-8 67505836
45
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
46
Ketoconazole Approved, Investigational Phase 4 65277-42-1, 142128-57-2 47576 3823 638701
47
Clarithromycin Approved Phase 4 81103-11-9 84029
48
Rifabutin Approved, Investigational Phase 4 72559-06-9 46783538 6323490
49
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
50
BCG vaccine Approved, Investigational Phase 4

Interventional clinical trials:

(show top 50) (show all 4015)
# Name Status NCT ID Phase Drugs
1 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
2 Assessment of Reactance Parameters Measured by the Forced Oscillation Technique for the Bronchodilator Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT03910985 Phase 4 Duovent HFA
3 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
4 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
5 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
6 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
7 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
8 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
9 Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT03551197 Phase 4 Budesonide and formoterol bid
10 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
11 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Unknown status NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
12 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
13 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
14 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
15 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Unknown status NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
16 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
17 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
18 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
19 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
20 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
21 Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep Unknown status NCT02150616 Phase 4 Oxygen;Sham oxygen (room air)
22 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
23 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
24 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
25 Effect of Doxofylline on Bronchial Obstruction, in add-on to Maximal Inhalation Therapy, in Clinically Stable COPD Patients. Unknown status NCT04238221 Phase 4 Doxofylline
26 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
27 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
28 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
29 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
30 The Effect of Twice Daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg vs. Once Daily Tiotropium 'Respimat' 5mcg on Static and Dynamic Hyperinflation in Patients With COPD During 24 Hours Unknown status NCT03275116 Phase 4 Tiotropium 'Respimat' 5 mcg;Aclidinium Bromide/Formoterol Fumarate 340/12 mcg
31 Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease: A Randomized, Multicenter Trial Investigating if Targeted Antibiotic Therapy Can Improve the Prognosis in COPD Patients Infected With Pseudomonas Aeruginosa Unknown status NCT03262142 Phase 4 Piperacillin/tazobactam;Ciprofloxacin
32 Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program Unknown status NCT03364829 Phase 4 Indacaterol/Glycopyrronium
33 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
34 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
35 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
36 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
37 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
38 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
39 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
40 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
41 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
42 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
43 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
44 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
45 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
46 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
47 Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Completed NCT01443845 Phase 4 Roflumilast;Placebo
48 Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Prospective Randomized Controlled Trial Completed NCT00882817 Phase 4
49 Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis Completed NCT03503188 Phase 4
50 Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). Completed NCT01957150 Phase 4 Fluticasone Furoate/Vilanterol;Vilanterol

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section

Genetic tests related to Lung Disease:

# Genetic test Affiliating Genes
1 Disorder of Lung 28
Sources

Anatomical Context for Lung Disease

About this section

Organs/tissues related to Lung Disease:

MalaCards : Lung, Bone Marrow, Heart, Neutrophil, Skeletal Muscle, Endothelial, Bronchial Epithelium
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 45519)
# Title Authors PMID Year
1
High diversity of clinical Mycobacterium intracellulare in China revealed by whole genome sequencing. 62 41
36466540 2022
2
Prenatal diagnosis of short-rib polydactyly syndrome type III or short-rib thoracic dysplasia 3 with or without polydactyly (SRTD3) associated with compound heterozygous mutations in DYNC2H1 in a fetus. 5
29458881 2018
3
Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease. 41
36439147 2022
4
Combination of anti-glycopeptidolipid-core IgA antibody and clinical features for diagnosing potential nontuberculous mycobacterium pulmonary disease in routine practice. 41
36444981 2022
5
Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. 53 62
20514434 2010
6
Characteristics of disorders associated with genetic mutations of surfactant protein C. 53 62
20403820 2010
7
Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. 53 62
20404089 2010
8
Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. 53 62
20511978 2010
9
Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. 53 62
20230362 2010
10
Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. 53 62
20082309 2010
11
Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. 53 62
20111696 2010
12
The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. 53 62
20423679 2010
13
Nrf2 protects against airway disorders. 53 62
19646463 2010
14
Long-term stability and circadian variation in circulating levels of surfactant protein D. 53 62
19540617 2010
15
Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. 53 62
20448817 2010
16
Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis. 53 62
19679607 2010
17
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. 53 62
19762563 2010
18
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 53 62
20082271 2010
19
4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. 53 62
19904934 2010
20
Development of carbohydrate-derived inhibitors of acid sphingomyelinase. 53 62
20005726 2010
21
Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. 53 62
19748599 2009
22
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. 53 62
19737146 2009
23
TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. 53 62
19850966 2009
24
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. 53 62
19603002 2009
25
Surfactant protein C in canine pulmonary fibrosis. 53 62
19747194 2009
26
Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts. 53 62
19734317 2009
27
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. 53 62
19759179 2009
28
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. 53 62
19797509 2009
29
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. 53 62
19443536 2009
30
Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis. 53 62
19596836 2009
31
Methemoglobin to cumulative nitric oxide ratio and response to inhaled nitric oxide in PPHN. 53 62
19554014 2009
32
Histone deacetylase-2 and airway disease. 53 62
19812111 2009
33
Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats. 53 62
19690261 2009
34
Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. 53 62
19375295 2009
35
Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. 53 62
19242722 2009
36
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. 53 62
19251783 2009
37
Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. 53 62
19372250 2009
38
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. 53 62
19596921 2009
39
New surfactant protein C gene mutations associated with diffuse lung disease. 53 62
19443464 2009
40
Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. 53 62
19097983 2009
41
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. 53 62
19349911 2009
42
IL1B polymorphisms modulate cystic fibrosis lung disease. 53 62
19431193 2009
43
Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. 53 62
19329540 2009
44
Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3. 53 62
19292764 2009
45
Generation of bleomycin-induced lung fibrosis is independent of IL-16. 53 62
19232499 2009
46
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. 53 62
19242412 2009
47
Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. 53 62
19466271 2009
48
Unimpaired lysosomal acidification in respiratory epithelial cells in cystic fibrosis. 53 62
19136560 2009
49
Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. 53 62
19019191 2009
50
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. 53 62
19707408 2009
Sources

Variations for Lung Disease

About this section

ClinVar genetic disease variations for Lung Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 DYNC2H1 NM_001377.3(DYNC2H1):c.5920G>T (p.Gly1974Ter) SNV Likely Pathogenic
 978635 rs1861879186 GRCh37: 11:103048330-103048330
GRCh38: 11:103177601-103177601
2 DYNC2H1 NM_001377.3(DYNC2H1):c.9908T>C (p.Ile3303Thr) SNV Uncertain Significance
 978634 rs1864508827 GRCh37: 11:103114510-103114510
GRCh38: 11:103243781-103243781
3 ABCA3 NM_001089.3(ABCA3):c.3613G>A (p.Gly1205Arg) SNV Uncertain Significance
 884386 rs549977217 GRCh37: 16:2334870-2334870
GRCh38: 16:2284869-2284869
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section


Pathways directly related to Lung Disease:

# Pathway Source
1 Diseases associated with surfactant metabolism Reactome 66

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 66
Show member pathways
 13.91 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
2
Innate Immune System 66
Show member pathways
 13.86 CCL2 CXCL8 ELANE IFIH1 IL10 IL1B
3
Disease 66
Show member pathways
 13.73 ABCA3 CFTR IFIH1 IL10 IL1B MUC5B
4
Toll-like receptor signaling pathway 74
Show member pathways
 12.8 CXCL8 IFIH1 IL1B SFTPA2 SFTPD TNF
5
Diseases of glycosylation 66
Show member pathways
 12.63 ABCA3 MUC5B SFTPA1 SFTPA2 SFTPB SFTPC
6
IL-1 Family Signaling Pathways 65
Show member pathways
 12.58 CFTR CXCL8 IL1B MUC5B TNF
7
Immune response IL-23 signaling pathway 22
Show member pathways
 12.55 TNF ITGA3 IL1B IL10 CCL2
8
NF-kappaB Signaling 3
12.53 TNF IL1B IL10 IFIH1 CCL2
9
Bacterial infections in CF airways 22
Show member pathways
 12.33 TNF SFTPD SFTPA1 IL1B CXCL8 CFTR
10
IL-17 Family Signaling Pathways 65
Show member pathways
 12.21 TNF MUC5B CXCL8 CFTR CCL2
11
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.14 TNF IL1B IL10 CXCL8
12
Spinal cord injury 74
11.95 TNF IL1B CXCL8 CCL2
13
IL27-mediated signaling events 61
Show member pathways
 11.86 TNF IL1B IL10
14
CCL18 signaling pathway 74
11.84 IL10 CXCL8 CCL2
15
Allograft rejection 74
11.84 TNF IL1B IL10 CXCL8
16
Interleukin-4 and Interleukin-13 signaling 66
11.84 TNF IL1B IL10 CXCL8 CCL2
17
Innate Lymphoid Cells Differentiation 65
11.75 TNF IL1B IL10
18
Burn wound healing 74
11.72 TNF IL1B CXCL8 CCL2
19
Dendritic Cells Developmental Lineage Pathway 65
11.71 TNF IL1B IL10
20
AP-1 transcription factor network 61
11.68 CCL2 CXCL8 IL10
21
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.63 TNF IL1B CXCL8
22
IL 10 signaling pathway 67
11.62 TNF IL1B IL10
23
miRNAs involvement in the immune response in sepsis 74
11.6 TNF IL10 ELANE CXCL8
24
Netrin-UNC5B signaling pathway 74
11.54 TNF IL10 CCL2
25
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.53 TNF CXCL8 CCL2
26
MSP-RON Signaling 64
11.49 TNF IL1B CCL2
27
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.49 TNF IL10 CXCL8 CCL2
28
IL-10 Pathway 64
11.33 TNF IL1B IL10
29
Interleukin-10 signaling 66
11.33 CCL2 CXCL8 IL10 IL1B TNF
30
Cytokines and inflammatory response 74
11.22 TNF IL1B IL10
31
Immune infiltration in pancreatic cancer 74
11.18 TNF IL10 CXCL8
32
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.15 TNF IL1B CXCL8 CCL2
33
Lung fibrosis 74
11.08 TNF SFTPC SFTPA2 SFTPA1 SERPINA1 MUC5B
34
Prostaglandin signaling 74
11.07 TNF IL1B CXCL8 CCL2
35
Surfactant metabolism 66
Show member pathways
 11.01 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
36
G-protein signaling_Rap2B regulation pathway 22
10.99 TNF ITGA3 IL1B IL10 CXCL8 CCL2
37
LDL Oxidation in Atherogenesis 64
10.92 TNF IL1B CCL2
38
Defective CSF2RA causes SMDP4 66
Show member pathways
 10.78 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
39
COVID-19 adverse outcome pathway 74
10.67 CXCL8 CCL2
40
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.34 TNF CXCL8
Sources

GO Terms for Lung Disease

About this section

Cellular components related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.39 CCL2 CXCL8 ELANE IL10 IL1B MUC5B
2 extracellular space GO:0005615 10.13 ABCA3 CCL2 CXCL8 ELANE IL10 IL1B
3 multivesicular body GO:0005771 9.97 SFTPD SFTPB SFTPA2 SFTPA1
4 clathrin-coated endocytic vesicle GO:0045334 9.85 SFTPA1 SFTPA2 SFTPB SFTPC SFTPD
5 alveolar lamellar body GO:0097208 9.8 SFTPC SFTPB ABCA3
6 multivesicular body lumen GO:0097486 9.71 SFTPC SFTPB
7 lamellar body GO:0042599 9.32 SFTPC SFTPB SFTPA2 SFTPA1 ABCA3

Biological processes related to Lung Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.99 TNF IL1B IL10 ELANE
2 positive regulation of phagocytosis GO:0050766 9.97 TNF SFTPD IL1B
3 lipopolysaccharide-mediated signaling pathway GO:0031663 9.91 TNF IL1B CCL2
4 cellular response to lipopolysaccharide GO:0071222 9.91 TNF IL1B IL10 CXCL8 CCL2
5 vascular endothelial growth factor production GO:0010573 9.83 TNF IL1B
6 negative regulation of cytokine production involved in immune response GO:0002719 9.78 TNF IL10
7 positive regulation of fever generation GO:0031622 9.76 TNF IL1B
8 sequestering of triglyceride GO:0030730 9.71 TNF IL1B
9 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.67 IL1B TNF
10 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B IL10
11 chronic inflammatory response to antigenic stimulus GO:0002439 9.62 TNF IL10
12 leukocyte migration GO:0050900 9.35 TNF ITGA3 IL1B ELANE
13 respiratory gaseous exchange by respiratory system GO:0007585 9.32 SFTPD SFTPC SFTPB SFTPA2 SFTPA1

Molecular functions related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.56 TNF SERPINA1 ITGA3 ELANE
2 cytokine activity GO:0005125 9.23 TNF IL1B IL10 CXCL8 CCL2
Sources

Sources for Lung Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....